Abstract:Gingival matrix haemorrhage (GMH) and intraventricular haemorrhage (IVH) are major neonatal disorders causing white matter damage (WMI) and neurological impairments in surviving neonates. Preclinical and clinical IVH research has advanced our understanding of the mechanisms driving IVH-induced WMI, including negative effects on oligodendrocyte progenitor cells (OPCs) and blood-generated axons, especially iron and thrombin.Right now, rehabilitation is the sole therapy option. As a result, new treatments must be developed faster to boost these neonates' outcomes. The most promising therapies in IVH124,147,151 infants are blood clot clearance (DRIFT or endoscopic lavage), early intervention (ELVIS), and stem cell transplantation.However, several barriers must be overcome before the findings of this research can be utilized in clinical practice, as both surgical intervention and intraventricular injection have inherent hazards and adverse effects. Brain damage is projected to be decreased by thorough neuro-endoscopic ventricular lavage surgery, and the optimal distribution strategy for stem cells is projected to enhance their therapeutic advantages. Therapy must begin before scarring and permanent damage develop in neonates with IVH, so determining the appropriate treatment window is critical for success.DRIFT clinical research was carried out in newborns with IVH at a median age of 20 days, and some improvements were found, but not as many as expected147.The median age of intervention in ELVIS was 9 days, leading to the lowest ventriculoperitoneal shunt rate observed in neonates with IVH to date and superior results at 2 years111. Nevertheless, prudence is suggested since early surgery may worsen IVH and aggravate damage.Several mechanism-targeted therapies were explored in preclinical animals. Oral or intramuscular thyroxine or celecoxib appear to be the most promising therapy in animal studies, as these drugs were previously granted to humans by the FDA, are straightforward to give and have low adverse-effect profiles. However, iron chelators or anti-thrombin treatment may be poorly tolerated and associated with significant adverse effects.Because the population of people with IVH is so different, a tailored approach to therapy selection may be needed. Blood clot removal, for example, is suitable for babies with grade III IVH but not isolated PVHI. Similarly, regenerative treatments and agents that reduce inflammation and oxidative stress in the brain (such as celecoxib, antioxidants, thyroxine, and stem cells) are likely to be most effective in infants with moderate to severe IVH, while the risk of side effects may limit their use in infants with IVH grade. Other frequent concerns in premature neonates include severe respiratory distress syndrome, low blood pressure, infection, patent ductus arteriosus, and low platelet levels, all of which may delay treatment. Despite these hurdles, feasible therapeutic solutions for neonates with IVH do not seem too far away.

Pharmacological neuroprotection and clinical trials of novel therapies for neonatal peri-intraventricular hemorrhage: a comprehensive review

Pharmacological Strategies and Surgical Management of Posthemorrhagic Hydrocephalus Following Germinal Matrix-Intraventricular Hemorrhage in Preterm Infants

Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges

Gingival and intraventricular haemorrhages are severe newborn diseases causing damage to white matter and neurological dysfunction in surviving newborns who can benefit from gene therapy

Pharmacological neuroprotection after perinatal asphyxia

Recovery of the brain after intraventricular hemorrhage

Preterm brain injury: Germinal matrix-intraventricular hemorrhage and post-hemorrhagic ventricular dilatation

Preterm neuroimaging and neurodevelopmental outcome: a focus on intraventricular hemorrhage, post-hemorrhagic hydrocephalus, and associated brain injury

Navigating the Complexities of Intraventricular Hemorrhage in Preterm Infants: An Updated Review

Preventing Brain Injury in the Preterm Infant—Current Controversies and Potential Therapies

New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

Clinical Evidence for the Prevention of Periventricular Hemorrhage-Intraventricular Hemorrhage in Preterm Infants

The Regulated Cell Death and Potential Interventions in Preterm Infants after Intracerebral Hemorrhage

Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy

The role of stem cells in the management of neonatal posthemorrhagic hydrocephalus

Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges

Nutraceuticals in the Prevention of Neonatal Hypoxia–Ischemia: A Comprehensive Review of their Neuroprotective Properties, Mechanisms of Action and Future Directions

Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage

Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives

Integrating Clinical and Neuroimaging Markers to predict the onset of post-hemorrhagic ventricular dilatation in preterm neonates

Pathogenesis and Prevention of Fetal and Neonatal Brain Injury